American Journal of Cancer

, Volume 4, Issue 6, pp 359–372

The Proteasome as a Target for Cancer Treatment

Focus on Bortezomib
Review Article

Abstract

Targeted degradation of key regulatory proteins is an essential element of cell-cycle control. The proteasome plays a pivotal role in the degradation of such proteins and has, therefore, become an important therapeutic target for diseases involving cell proliferation, notably malignant diseases. Several studies have demonstrated that proteasome inhibition induces apoptosis and sensitizes cancer cells to traditional tumoricidal agents (chemotherapy or irradiation), both in vitroand in vivo, by having a significant impact on the turnover of certain key cell cycle regulatory elements (p53, p21, p27, Bax, etc.) as well as central transcription factors (nuclear factor [NF]-κB). Inhibition of the latter can result in reversal of chemoresistance.

Bortezomib, a potent and selective proteasome inhibitor, is particularly promising from a therapeutic perspective; it is the only such inhibitor that has progressed to clinical trials. Results from phase I/II studies indicate that the drug is well tolerated, and bortezomib has become an effective treatment for patients with hematologic malignancies (in particular multiple myeloma). This drug also seems to have significant activity in solid tumor malignancies. Phase I/II combination studies of bortezomib and other chemotherapeutics in hematologic and solid tumors are underway.

References

  1. 1.
    Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29 Suppl. 1: 3–9CrossRefGoogle Scholar
  2. 2.
    King RW, Deshaies RJ, Peters JM, et al. How proteolysis drives the cell cycle. Science 1996; 274: 1652–9PubMedCrossRefGoogle Scholar
  3. 3.
    Dahlmann B, Kopp F, Kuehn L, et al. The multicatalytic proteinase (prosome) is ubiquitous from eukaryotes to archaebacteria. FEBS Lett 1989; 251: 125–31PubMedCrossRefGoogle Scholar
  4. 4.
    Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425–79PubMedCrossRefGoogle Scholar
  5. 5.
    Eytan E, Ganoth D, Armon T, et al. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci U S A 1989; 86: 7751–5PubMedCrossRefGoogle Scholar
  6. 6.
    Zwickl P, Voges D, Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1501–11PubMedCrossRefGoogle Scholar
  7. 7.
    Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739–58PubMedCrossRefGoogle Scholar
  8. 8.
    Lupas A, Koster AJ, Baumeister W. Structural features of 26S and 20S proteasomes. Enzyme Protein 1993; 47: 252–73PubMedGoogle Scholar
  9. 9.
    Dick TP, Nussbaum AK, Deeg M, et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem 1998; 273: 25637–46PubMedCrossRefGoogle Scholar
  10. 10.
    Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A 1998; 95: 12504–9PubMedCrossRefGoogle Scholar
  11. 11.
    Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761–71PubMedCrossRefGoogle Scholar
  12. 12.
    Heinemeyer W, Fischer M, Krimmer T, et al. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997; 272: 25200–9PubMedCrossRefGoogle Scholar
  13. 13.
    Roth AF, Davis NG. Ubiquitination of the PEST-like endocytosis signal of the yeast a-factor receptor. J Biol Chem 2000; 275: 8143–53PubMedCrossRefGoogle Scholar
  14. 14.
    Marchai C, Haguenauer-Tsapis R, Urban-Grimal D. A PEST-like sequence mediates phosphorylation and efficient ubiquitination of yeast uracil permease. Mol Cell Biol 1998; 18: 314–21Google Scholar
  15. 15.
    Lee PL, Midelfort CF, Murakami K, et al. Multiple forms of ubiquitin-protein ligase. Binding of activated ubiquitin to protein substrates. Biochemistry 1986; 25: 3134–8PubMedCrossRefGoogle Scholar
  16. 16.
    Kisselev AF, Songyang Z, Goldberg AL. Why does threonine, and not serine, function as the active site nucleophile in proteasomes? J Biol Chem 2000; 275: 14831–7PubMedCrossRefGoogle Scholar
  17. 17.
    Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373–428PubMedGoogle Scholar
  18. 18.
    Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333–8PubMedCrossRefGoogle Scholar
  19. 19.
    Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14: 628–34PubMedCrossRefGoogle Scholar
  20. 20.
    Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex: properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 1993; 32: 1563–72PubMedCrossRefGoogle Scholar
  21. 21.
    Palmer JT, Rasnick D, Klaus JL, et al. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995; 38: 3193–6PubMedCrossRefGoogle Scholar
  22. 22.
    Bogyo M, McMaster JS, Gaczynska M, et al. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia colihomolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A 1997; 94: 6629–34PubMedCrossRefGoogle Scholar
  23. 23.
    Dick LR, Cruikshank AA, Grenier L, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 1996; 271: 7273–6PubMedCrossRefGoogle Scholar
  24. 24.
    Fenteany G, Standaert RF, Lane WS, et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268: 726–31PubMedCrossRefGoogle Scholar
  25. 25.
    Ostrowska H, Wojcik C, Omura S, et al. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun 1997; 234: 729–32PubMedCrossRefGoogle Scholar
  26. 26.
    Geier E, Pfeifer G, Wilm M, et al. A giant protease with potential to substitute for some functions of the proteasome. Science 1999; 283: 978–81PubMedCrossRefGoogle Scholar
  27. 27.
    Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999; 96: 10403–8PubMedCrossRefGoogle Scholar
  28. 28.
    Koguchi Y, Kohno J, Nishio M, et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093: taxonomy, production, isolation, and biological activities. J Antibiot (Tokyo) 2000; 53: 105–9CrossRefGoogle Scholar
  29. 29.
    Kroll M, Arenzana-Scisdedos F, Bachelerie F, et al. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol 1999; 6: 689–98PubMedCrossRefGoogle Scholar
  30. 30.
    Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276: 13322–30PubMedCrossRefGoogle Scholar
  31. 31.
    Chung FL, Schwartz J, Herzog CR, et al. Tea and cancer prevention: studies in animals and humans. J Nutr 2003; 133(10): 3268S–74SPubMedGoogle Scholar
  32. 32.
    Siddiqui IA, Afaq F, Adhami VM, et al. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004; 6: 571–82PubMedCrossRefGoogle Scholar
  33. 33.
    Kane RC, Bross PF, Farrell AT, et al. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508–13PubMedCrossRefGoogle Scholar
  34. 34.
    An WG, Hwang SG, Trepel JB, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAFl/CIPl, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276–83PubMedCrossRefGoogle Scholar
  35. 35.
    Wu Y, Luo H, Kanaan N, et al. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000; 76: 596–604PubMedCrossRefGoogle Scholar
  36. 36.
    MacLaren AP, Chapman RS, Wyllie AH, et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8: 210–8PubMedCrossRefGoogle Scholar
  37. 37.
    Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997; 94: 855–60PubMedCrossRefGoogle Scholar
  38. 38.
    Ciechanover A, DiGiuseppe JA, Bercovich B, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 1991; 88: 139–43PubMedCrossRefGoogle Scholar
  39. 39.
    Chowdary DR, Dermody JJ, Jha KK, et al. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994; 14: 1997–2003PubMedGoogle Scholar
  40. 40.
    Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(l). Cancer Res 1996; 56: 2649–54PubMedGoogle Scholar
  41. 41.
    Dietrich C, Bartsch T, Schanz F, et al. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc Natl Acad Sci U S A 1996; 93: 10815–9PubMedCrossRefGoogle Scholar
  42. 42.
    Blagosklonny MV, Wu GS, Omura S, et al. Proteasome-dependent regulation of p21WAFl/CIPl expression. Biochem Biophys Res Commun 1996; 227: 564–9PubMedCrossRefGoogle Scholar
  43. 43.
    Shinohara K, Tomioka M, Nakano H, et al. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996; 317(Pt 2): 385–8PubMedGoogle Scholar
  44. 44.
    Kurland JF, Meyn RE. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int J Cancer 2001; 96: 327–33PubMedCrossRefGoogle Scholar
  45. 45.
    Lopes UG, Erhardt P, Yao R, et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893–6PubMedCrossRefGoogle Scholar
  46. 46.
    An B, Goldfarb RH, Siman R, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062–75PubMedCrossRefGoogle Scholar
  47. 47.
    Naujokat C, Sezer O, Zinke H, et al. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000; 65: 221–36PubMedCrossRefGoogle Scholar
  48. 48.
    Herrmann JL, Beham AW, Sarkiss M, et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 1997; 237: 101–9PubMedCrossRefGoogle Scholar
  49. 49.
    Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82: 110–22PubMedCrossRefGoogle Scholar
  50. 50.
    Machiels BM, Henfling ME, Gerards WL, et al. Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 1997; 28: 243–52PubMedCrossRefGoogle Scholar
  51. 51.
    Ahrendt SA, Brown HM, Komorowski RA, et al. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 2000; 128: 520–30PubMedCrossRefGoogle Scholar
  52. 52.
    Loda M, Cukor B, Tarn SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231–4PubMedCrossRefGoogle Scholar
  53. 53.
    Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227–30PubMedCrossRefGoogle Scholar
  54. 54.
    Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclindependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619–26PubMedGoogle Scholar
  55. 55.
    Chen F, Chang D, Goh M, et al. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000; 11: 239–46PubMedGoogle Scholar
  56. 56.
    Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–22PubMedGoogle Scholar
  57. 57.
    Grimm LM, Goldberg AL, Poirier GG, et al. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996; 15: 3835–44PubMedGoogle Scholar
  58. 58.
    Sadoul R, Fernandez PA, Quiquerez AL, et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996; 15: 3845–52PubMedGoogle Scholar
  59. 59.
    Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000; 97: 3850–5PubMedCrossRefGoogle Scholar
  60. 60.
    Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95: 176–80PubMedCrossRefGoogle Scholar
  61. 61.
    Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003; 2: 199–201PubMedGoogle Scholar
  62. 62.
    Meriin AB, Gabai VL, Yaglom J, et al. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998; 273: 6373–9PubMedCrossRefGoogle Scholar
  63. 63.
    Tsurumi C, Ishida N, Tamura T, et al. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol Cell Biol 1995; 15: 5682–7PubMedGoogle Scholar
  64. 64.
    Gross-Mesilaty S, Reinstein E, Bercovich B, et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci U S A 1998; 95: 8058–63PubMedCrossRefGoogle Scholar
  65. 65.
    Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999; 18: 849–54PubMedCrossRefGoogle Scholar
  66. 66.
    Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129–57PubMedGoogle Scholar
  67. 67.
    Askew DS, Ashmun RA, Simmons BC, et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915–22PubMedGoogle Scholar
  68. 68.
    Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773–85Google Scholar
  69. 69.
    Lin YC, Brown K, Siebenlist U. Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc Natl Acad Sci U S A 1995; 92: 552–6PubMedCrossRefGoogle Scholar
  70. 70.
    Roff M, Thompson J, Rodriguez MS, et al. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 1996; 271: 7844–50PubMedCrossRefGoogle Scholar
  71. 71.
    Kucharczak J, Simmons MJ, Fan Y, et al. To be, or not to be: NF-kappaB is the answer -role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961–82PubMedCrossRefGoogle Scholar
  72. 72.
    Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–10PubMedCrossRefGoogle Scholar
  73. 73.
    Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649–83PubMedCrossRefGoogle Scholar
  74. 74.
    Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241–6PubMedCrossRefGoogle Scholar
  75. 75.
    Scherer DC, Brockman JA, Chen Z, et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A 1995; 92: 11259–63PubMedCrossRefGoogle Scholar
  76. 76.
    Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9: 1586–97PubMedCrossRefGoogle Scholar
  77. 77.
    Winston JT, Strack P, Beer-Romero P, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999; 13: 270–83PubMedCrossRefGoogle Scholar
  78. 78.
    Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004; 64: 5036–43PubMedCrossRefGoogle Scholar
  79. 79.
    Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853–66PubMedCrossRefGoogle Scholar
  80. 80.
    Brown K, Park S, Kanno T, et al. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci U S A 1993; 90: 2532–6PubMedCrossRefGoogle Scholar
  81. 81.
    Yin L, Hubbard AK, Giardina C. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J Biol Chem 2000; 275: 36671–5PubMedCrossRefGoogle Scholar
  82. 82.
    Gilmore TD, Koedood M, Piffat KA, et al. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 1996; 13: 1367–78PubMedGoogle Scholar
  83. 83.
    Moore BE, Bose Jr HR. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology 1988; 162: 377–87PubMedCrossRefGoogle Scholar
  84. 84.
    Sylla BS, Temin HM. Activation of oncogenicity of the c-rel proto-oncogene. Mol Cell Biol 1986; 6: 4709–16PubMedGoogle Scholar
  85. 85.
    Wang CY, Cusack JrJC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412–7PubMedCrossRefGoogle Scholar
  86. 86.
    Bentires-Alj M, Hellin AC, Ameyar M, et al. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999; 59: 811–5PubMedGoogle Scholar
  87. 87.
    Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002; 21: 6510–9PubMedCrossRefGoogle Scholar
  88. 88.
    Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6: 3719–28PubMedGoogle Scholar
  89. 89.
    Delie J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77: 1103–7CrossRefGoogle Scholar
  90. 90.
    Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784–7PubMedCrossRefGoogle Scholar
  91. 91.
    Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624–31PubMedGoogle Scholar
  92. 92.
    Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100: 11–7PubMedCrossRefGoogle Scholar
  93. 93.
    Cusack JrJC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535–40PubMedGoogle Scholar
  94. 94.
    Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638–45PubMedGoogle Scholar
  95. 95.
    Russo SM, Tepper JE, Baldwin Jr AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183–93PubMedCrossRefGoogle Scholar
  96. 96.
    McConkey DJ, Williams SA, Papandreou C. Role of p53 in proteasome inhibitor-based combination chemotherapy in LNCaP cells [abstract]. Proc Am Assoc Cancer Res 2000; 42: 651Google Scholar
  97. 97.
    McConkey DJ, Williams SA, Logothetis CJ, et al. Preclinical evaluation of proteasome inhibitor-based combination chemotherapy for advanced prostate cancer. Proc Am Assoc Cancer Res 2001; 42: 229–30Google Scholar
  98. 98.
    Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220–9PubMedGoogle Scholar
  99. 99.
    Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000; 47: 1025–32PubMedCrossRefGoogle Scholar
  100. 100.
    Yang H, Assikis V, Daliani D, et al. The proteasome inhibitor PS-341 alters the chemosensitivity of prostate cancer cells [abstract]. Proc Am Assoc Cancer Res 2003; 44: 1495Google Scholar
  101. 101.
    Pervan M, Pajonk F, Sun JR, et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001; 24: 481–5PubMedCrossRefGoogle Scholar
  102. 102.
    Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419–28PubMedGoogle Scholar
  103. 103.
    Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1: 1243–53PubMedGoogle Scholar
  104. 104.
    Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. Oncologist 2002; 7 Suppl. 1: 20–9CrossRefGoogle Scholar
  105. 105.
    Feinman R, Koury J, Thames M, et al. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044–52PubMedGoogle Scholar
  106. 106.
    Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001; 28: 626–33PubMedCrossRefGoogle Scholar
  107. 107.
    Grisham MB, Palombella VJ, Elliott PJ, et al. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999; 300: 345–63PubMedCrossRefGoogle Scholar
  108. 108.
    Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519–27PubMedCrossRefGoogle Scholar
  109. 109.
    Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–47PubMedCrossRefGoogle Scholar
  110. 110.
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–80PubMedCrossRefGoogle Scholar
  111. 111.
    Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–74PubMedCrossRefGoogle Scholar
  112. 112.
    Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88–95PubMedGoogle Scholar
  113. 113.
    Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62: 1083–6PubMedGoogle Scholar
  114. 114.
    Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–6PubMedGoogle Scholar
  115. 115.
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99: 14374–9PubMedCrossRefGoogle Scholar
  116. 116.
    Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105: 752–7PubMedCrossRefGoogle Scholar
  117. 117.
    Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9–16PubMedCrossRefGoogle Scholar
  118. 118.
    LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996–5000PubMedGoogle Scholar
  119. 119.
    Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673–83PubMedGoogle Scholar
  120. 120.
    O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46: 33–48PubMedCrossRefGoogle Scholar
  121. 121.
    Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505–11PubMedGoogle Scholar
  122. 122.
    Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–7PubMedCrossRefGoogle Scholar
  123. 123.
    Logothetis CJ, Yang H, Daliani D, et al. Dose dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341 [abstract]. Proc Am Assoc Cancer Res 2001; 20: 186aGoogle Scholar
  124. 124.
    Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159–65PubMedCrossRefGoogle Scholar
  125. 125.
    Twillie DA, Eisenberger MA, Carducci MA, et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542–9PubMedCrossRefGoogle Scholar
  126. 126.
    Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633–9PubMedGoogle Scholar
  127. 127.
    Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108–21PubMedCrossRefGoogle Scholar
  128. 128.
    Raza A, Lisak LA, Tahir S, et al. Myelodysplastic syndrome patients show a variety of hematologie responses to proteasome inhibitor bortezomib (PS 341) [abstract]. Blood 2002; 100: 338bGoogle Scholar
  129. 129.
    Hamilton AL, Eder J, Pavlick AC, et al. PS-341: phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints [abstract]. Proc Am Soc Clin Oncol 2001; 20: 85aGoogle Scholar
  130. 130.
    Gy GK, Thomas JP, Wilding G, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005; 11(9): 3410–6CrossRefGoogle Scholar
  131. 131.
    Iqbal S, Lenz HJ, Groshen S, et al. Phase I study of PS-341 in combination with 5-FU/LV in solid tumors [abstract]. Proc Am Soc Clin Oncol 2002; 21: 93aGoogle Scholar
  132. 132.
    Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371–6PubMedCrossRefGoogle Scholar
  133. 133.
    Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127(2): 165–72PubMedCrossRefGoogle Scholar
  134. 134.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–17PubMedCrossRefGoogle Scholar
  135. 135.
    Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10(18 Pt 1): 6111–8PubMedCrossRefGoogle Scholar
  136. 136.
    Thomas JP, Arzoomanian R, Alberti D, et al. A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin [abstract]. Proc Am Soc Clin Oncol 2002; 21: 93aGoogle Scholar
  137. 137.
    O’Connor O, Wright J, Moskowitz CH, et al. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular and mantle cell lymphoma. J Clin Oncol 2005; 23(4): 676–84PubMedCrossRefGoogle Scholar
  138. 138.
    Goy A, Younes A, McLaughlin P, et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). J Clin Oncol 2005; 23(4): 667–75PubMedCrossRefGoogle Scholar
  139. 139.
    Clark JW, Ryan D, Dees C, et al. Phase I dose-escalation study of the proteasome inhibitor PS-341, plus irinotecan in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2002; 21: 93aGoogle Scholar
  140. 140.
    Ryan DP, Eder JP, Winkelmann J, et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2002; 21: 95aGoogle Scholar
  141. 141.
    Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologie malignancies. Blood 2005; 102(8): 3058–65CrossRefGoogle Scholar
  142. 142.
    Zangari M, Barlogie B, Prather J, et al. Marked activity also in Del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies [abstract]. Blood 2002; 100: 105aCrossRefGoogle Scholar
  143. 143.
    Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–23PubMedCrossRefGoogle Scholar
  144. 144.
    Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dex-amethasone for relapsed muliple myeloma. N Engl J Med 2005; 352(24): 287–98CrossRefGoogle Scholar
  145. 145.
    Jagannath S, Durie BGM, Wolf J, et al. First-line therapy with bortezomib (VELCADE®, Formerly PS-341) in patients with multiple myeloma (MM) [abstract]. J Clin Oncol 2004; 22Suppl 14s: 570sGoogle Scholar
  146. 146.
    Cavenagh J, Curry N, Stec J, et al. PAD Therapy (Bortezomib, Adriamycin and dexamethasone) for untreated Multiple Myeloma (MM) [abstract]. J Clin Oncol 2004; 22Suppl 14s: 570sGoogle Scholar
  147. 147.
    Yang HH, Vescio R, Schenkein D, et al. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 2003; 4: 119–22PubMedCrossRefGoogle Scholar
  148. 148.
    Zangari M, Barlogie B, Jacobson J, et al. VTD regimen comprising Velcade (V) + Thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant [abstract]. Blood 2003; 102: 236aGoogle Scholar
  149. 149.
    Jagannath S, Richardson P, Barlogie B, et al. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone [abstract no. 2341]. Proc Am Soc Clin Oncol 2003; 22: 582Google Scholar
  150. 150.
    Shaughnessy J, Zhan F, McCastlain K, et al. Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341 [abstract]. Blood 2002; 100: 390aGoogle Scholar
  151. 151.
    Shaughnessy J, Zhan F, Kordsmeier B, et al. Gene expression profiling (GEP) after short term in-vivo treatment identifies potential mechanisms of action of current drugs used to treat multiple myeloma [abstract]. Blood 2002; 100: 208aCrossRefGoogle Scholar
  152. 152.
    Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. Epub 2005 Jul 14Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.The University of Texas, M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Medical OncologySchool of Medicine, University of ThessalyHellasGreece

Personalised recommendations